Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 2/20 | 0.47 |
| ▸ | ENTPD5 | O75356 | 1/20 | 0.47 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8148354 | 0.62 | CETP (0.51) | CETPENTPD5 | |
| Strongylin A SCHEMBL31536139 | 0.61 | CETP (1.00) | CETPENTPD5ALOX15ALOX12 | |
| Strongylin A SCHEMBL8273902 | 0.61 | CETP (1.00) | CETPENTPD5ALOX15ALOX12 | |
| SCHEMBL16984748 | 0.55 | CETP (0.39) | CETPENTPD5PTPN1 | |
| SCHEMBL3146702 | 0.53 | PIK3CA (0.42) | CETPALOX5ALOX15ALOX12 | |
| SCHEMBL14813240 | 0.53 | ALOX15 (0.68) | ALOX5ALOX15ALOX12 | |
| SCHEMBL9839543 | 0.52 | PAX8 (0.33) | — | |
| SCHEMBL3536691 | 0.52 | CA1 (0.38) | CETPENTPD5ALOX5ALOX15ALOX12 | |
| SCHEMBL9730930 | 0.50 | MAPT (0.39) | ALOX15PTPN1 | |
| SCHEMBL6438246 | 0.50 | CYP19A1 (0.40) | CETPALOX5ALOX15ALOX12PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250122146-A1 | COMPOUNDS FOR REDUCING NEUROINFLAMMATION | THE SCRIPPS RESEARCH INSTITUTE | 2025-04-17 | — | — | US | claimed |
| US-20250122146-A1 | COMPOUNDS FOR REDUCING NEUROINFLAMMATION | THE SCRIPPS RESEARCH INSTITUTE | 2025-04-17 | — | — | US | disclosed |
| WO-2024226703-A2 | ASYMMETRIC SYNTHESIS AND DIVERSIFICATION OF A STABILIZED SALVINORIN A SCAFFOLD | THE SCRIPPS RESEARCH INSTITUTE (US) | 2024-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122146-A1 | COMPOUNDS FOR REDUCING NEUROINFLAMMATION | HSF1, HSPA2, KEAP1 | CETP 4053/4885ENTPD5 4851/4885CDK2 1812/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.